Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone
Alimentary Pharmacology & Therapeutics2022Vol. 57(5), pp. 464–474
Citations Over TimeTop 10% of 2022 papers
Jian Wang, Xiaomin Yan, Li Zhu, Jiacheng Liu, Yuanwang Qiu, Y. G. Li, Yilin Liu, Ruifei Xue, Jie Zhan, Suling Jiang, Yu Geng, Yawen Wan, Ming Li, Minxin Mao, Dongmei Gao, Shengxia Yin, Xin Tong, Juan Xia, Weimao Ding, Yuxin Chen, Jie Li, Chuanwu Zhu, Rui Huang, Chao Wu
Abstract
Over 70% of GZ CHB patients had significant histological disease. We recommend antiviral treatment for HBeAg-positive and HBeAg-negative GZ CHB patients with high PT.
Related Papers
- → Anti-HBV agents. Part 2: Synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives(2009)32 cited
- → Quantitative analysis of wild-type and precore mutant hepatitis B virus in carriers(2002)9 cited
- Inhibitory effect of novel polyoxometalate on hepatitis B virus replication in vitro(2007)
- Comparison of HBV-M and HBV-DNA detection in HBV infectors in the North of Anhui(2013)
- Relationship among HBV Serum Markers, Pre-C 1896 Mutant and Virus Loading(2001)